Prevalencia de pacientes con esquizofrenia asociada al consumo de cannabis en individuos mayores de 18 años en el Instituto de Neurociencias de Guayaquil en el año 2022.

Abstract

Introduction: The interaction between cannabis use and schizophrenia has been the subject of attention in the scientific literature for decades. Multiple studies have explored the association between cannabis use and an increased risk of developing psychotic disorders, including schizophrenia. Methodology: Retrospective, observational, descriptive study. Patients with schizophrenia over 18 years of age, who have a history of Cannabis consumption and who have been treated at the Institute of Neurosciences of Guayaquil during the year 2022. Results: To comply with the proposed objectives, the number of patients diagnosed with schizophrenia was analyzed. Schizophrenia who were treated during 2022 at the Institute of Neurosciences of Guayaquil, thus determining a prevalence of 53.5%. Discussion: In this study it was found that at least 53.5% of the patients studied had an association between Cannabis Use and Schizophrenia, which indicates that at least half of the patients studied have Cannabis consumption as a concomitant factor having a diagnosis of schizophrenia.